Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC September Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Testosterone 24 hours transdermal patch (Intrinsa®) has been rejected for the treatment of hypoactive sexual desire disorder (HSDD) in surgically induced menopausal women

Pioglitazone (Actos®) has been accepted for use in combination with insulin in type 2 diabetes mellitus patients.

Celecoxib (Celebrex®) has been rejected for use in ankylosing spondylitis. This rejection was made because the manufacturer failed to submit a New Product Assessment Form as required by the SMC evaluation process.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.

Share 'SMC September Update' on Email Share 'SMC September Update' on Delicious Share 'SMC September Update' on Digg Share 'SMC September Update' on Facebook Share 'SMC September Update' on Google+ Share 'SMC September Update' on reddit Share 'SMC September Update' on StumbleUpon Share 'SMC September Update' on Twitter

atomic-wealth

No Comments to “SMC September Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,309 spam comments.

atomic-wealth
fond-illness
summer